| Management target | Revenue 2027-30 |
|---|
| Revenue growth | 29.2% YoY for H1 FY27 |
|---|---|
| Margins | Gross Margins rose to 56.2% from 51.4% YoY |
| Demand visibility | Strong; 872 registrations in pipeline |
| Management confidence | High; citing Vision 2030 roadmap |
Growth
H1 FY27 Revenue grew 29.2% YoY; PAT increased to INR 34 Cr with 13.1% margin.
Outlook
Targeting INR 1,000 Cr revenue by FY30. Planned expansion of API capacity and entry into complex biosimilars.
Risks
Rising crude prices (+41.7%), spiking India WPI inflation (+10.05%), and geopolitical conflicts causing economic uncertainty.
Last quarter's promises, checked
Delivered
- Guided 20-25% annual revenue growth → delivered 29.2% (= BEAT)
- Guided EBITDA margins above 23% → delivered 23.2% (= BEAT)
- Guided Nivian to grow 30% → delivered 75% (= BEAT)
Partly delivered
- Guided 20-25 new products in 3-4 years → delivered 4 in H1 FY27 (= PARTIAL)
Missed
- Guided H1 FY27 export growth of 30% → delivered 18% contribution mix (= MISS)
Investor Presentation filed with NSE, NSE: BETA. Summary written with AI assistance from the document.
Beta Drugs Ltd: key numbers
- Share price
- ₹1,976.80
- Market cap
- ₹2,191 Cr
- Revenue (annual)
- ₹384.8 Cr
- Net profit (annual)
- ₹41.48 Cr
- P/E (TTM)
- 42.2×Sector 46.1×
- Promoter holding
- 58.91%-0.19% QoQ
- FII holding
- 1.37%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Beta Drugs Ltd
All →Beta Drugs Other Announcement
Beta Drugs Limited submitted its quarterly Statement of Deviation or Variation for the preferential issue proceeds, confirming no deviation from the stated objects.
Beta Drugs Earnings Call Transcript: Key Takeaways
Management projects a 20-25% growth trajectory despite Q2 bottlenecks. Recent acquisitions and niche oncology focus underpin expansion strategy.
- Call
- Guides 25% growth
Beta Drugs Q2 FY27 Results: Net Profit ₹185,507,075 Cr, Up 51.8% YoY
Beta Drugs Ltd reported revenue from operations of ₹1,374,887,594 Cr (+33.0% YoY) and net profit of ₹185,507,075 Cr (+51.8% YoY) for Q2 FY27.
- Key figure
- Net profit ₹185,507,075 Cr · +51.8% YoY
Beta Drugs Board Meeting Date
Beta Drugs Limited notified the exchange of a board meeting scheduled for 22-Oct-2026 to consider quarterly financial results. The trading window closure was also intimated.
Beta Drugs Annual General Meeting
Beta Drugs Limited conducted its 21st Annual General Meeting on September 30, 2026. Shareholders considered resolutions including financial statement adoption, director re-appointments, and auditor ratification.
Beta Drugs Business Update
Beta Drugs secured Azerbaijani regulatory approvals for its oncology portfolio across multiple dosage forms. The company targets Azerbaijan commercialisation during the current financial year.